🟢 ASBP is trading 6.7% up today as it recovers from acquisition concerns and eyes FDA momentum

ASBP is trading 6.7% up at $5.70 in pre-market, bouncing after yesterday’s sharp drop tied to fading optimism around its planned Dura Driver Control Systems acquisition.

• Traders are revisiting earlier bullish news regarding a successful FDA pre-IND meeting for OTASA, a sublingual aspirin heart-attack treatment.
• The FDA has cleared a streamlined regulatory path for the treatment, which previously caused the stock to surge over 60% in a single session.
• The current price action reflects a recovery in sentiment as investors balance M&A uncertainty against positive clinical milestones.